171 related articles for article (PubMed ID: 33763905)
1. Evaluation of grade in a genotyped cohort of sporadic medullary thyroid carcinomas.
Najdawi F; Ahmadi S; Capelletti M; Dong F; Chau NG; Barletta JA
Histopathology; 2021 Sep; 79(3):427-436. PubMed ID: 33763905
[TBL] [Abstract][Full Text] [Related]
2. International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma.
Xu B; Fuchs TL; Ahmadi S; Alghamdi M; Alzumaili B; Bani MA; Baudin E; Chou A; De Leo A; Fagin JA; Ganly I; Glover A; Hartl D; Kanaan C; Khneisser P; Najdawi F; Nigam A; Papachristos A; Repaci A; Spanheimer PM; Solaroli E; Untch BR; Barletta JA; Tallini G; Al Ghuzlan A; Gill AJ; Ghossein RA
J Clin Oncol; 2022 Jan; 40(1):96-104. PubMed ID: 34731032
[TBL] [Abstract][Full Text] [Related]
3. A Proposed Grading Scheme for Medullary Thyroid Carcinoma Based on Proliferative Activity (Ki-67 and Mitotic Count) and Coagulative Necrosis.
Fuchs TL; Nassour AJ; Glover A; Sywak MS; Sidhu SB; Delbridge LW; Clifton-Bligh RJ; Gild ML; Tsang V; Robinson BG; Clarkson A; Sheen A; Sioson L; Chou A; Gill AJ
Am J Surg Pathol; 2020 Oct; 44(10):1419-1428. PubMed ID: 32452872
[TBL] [Abstract][Full Text] [Related]
4. Novel RET mutations in macedonian patients with medullary thyroid carcinoma: genotype-phenotype correlations.
Jovanovic R; Kostadinova-Kunovska S; Janevska V; Bogoeva B; Spasevska L; Miladinova D; Ugrinska A; Zdraveska-Kochovska M; Trajkov D; Petrusevska G
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):93-107. PubMed ID: 26076779
[TBL] [Abstract][Full Text] [Related]
5. Grading of Medullary Thyroid Carcinoma: an Interobserver Reproducibility Study.
Williams JF; Zhao M; Najdawi F; Ahmadi S; Hornick JL; Wong KS; Barletta JA
Endocr Pathol; 2022 Sep; 33(3):371-377. PubMed ID: 35553368
[TBL] [Abstract][Full Text] [Related]
6. Independent Validation of the International Grading System for Medullary Thyroid Carcinoma: A Single Institution Experience.
Lubin DJ; Behrman DB; Goyal S; Magliocca K; Shi Q; Chen AY; Viswanathan K
Mod Pathol; 2023 Sep; 36(9):100235. PubMed ID: 37270155
[TBL] [Abstract][Full Text] [Related]
7. Medullary Thyroid Carcinoma: Survival Analysis and Evaluation of Mutation-Specific Immunohistochemistry in Detection of Sporadic Disease.
Jayakody S; Reagh J; Bullock M; Aniss A; Clifton-Bligh R; Learoyd D; Robinson B; Delbridge L; Sidhu S; Gill AJ; Sywak M
World J Surg; 2018 May; 42(5):1432-1439. PubMed ID: 29484475
[TBL] [Abstract][Full Text] [Related]
8. Correlation of molecular data with histopathological and clinical features in a series of 66 patients with medullary thyroid carcinoma.
Moura MM; Cabrera RA; Esteves S; Cavaco BM; Soares P; Leite V
J Endocrinol Invest; 2021 Sep; 44(9):1837-1846. PubMed ID: 33575974
[TBL] [Abstract][Full Text] [Related]
9. Grading medullary thyroid carcinoma on fine-needle aspiration cytology specimens with the International Medullary Thyroid Carcinoma Grading System: A cytologic-histologic correlation.
Viswanathan K; Behrman DB; Lubin DJ
Cancer Cytopathol; 2024 Apr; 132(4):224-232. PubMed ID: 38062948
[TBL] [Abstract][Full Text] [Related]
10. Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma.
Jung CK; Agarwal S; Hang JF; Lim DJ; Bychkov A; Mete O
Endocr Pathol; 2023 Mar; 34(1):1-22. PubMed ID: 36890425
[TBL] [Abstract][Full Text] [Related]
11. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.
Boichard A; Croux L; Al Ghuzlan A; Broutin S; Dupuy C; Leboulleux S; Schlumberger M; Bidart JM; Lacroix L
J Clin Endocrinol Metab; 2012 Oct; 97(10):E2031-5. PubMed ID: 22865907
[TBL] [Abstract][Full Text] [Related]
12. The prevalence of somatic RAS mutations in medullary thyroid cancer - a Polish population study.
Oczko-Wojciechowska M; Pfeifer A; Rusinek D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Kowal M; Swierniak M; Krajewska J; Gawlik T; Chmielik E; Czarniecka A; Szpak-Ulczok S; Jarząb B
Endokrynol Pol; 2015; 66(2):121-5. PubMed ID: 25931041
[TBL] [Abstract][Full Text] [Related]
13. Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification.
Mian C; Pennelli G; Barollo S; Cavedon E; Nacamulli D; Vianello F; Negro I; Pozza G; Boschin IM; Pelizzo MR; Rugge M; Mantero F; Girelli ME; Opocher G
Eur J Endocrinol; 2011 Jun; 164(6):971-6. PubMed ID: 21422198
[TBL] [Abstract][Full Text] [Related]
14. External Validation of Three Available Grading Systems for Medullary Thyroid Carcinoma in a Single Institution Cohort.
Vissio E; Maletta F; Fissore J; Osella Abate S; Retta F; Brizzi MP; Piovesan A; Rossetto Giaccherino R; Volante M; Papotti M
Endocr Pathol; 2022 Sep; 33(3):359-370. PubMed ID: 35583706
[TBL] [Abstract][Full Text] [Related]
15. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma.
Marsh DJ; Learoyd DL; Andrew SD; Krishnan L; Pojer R; Richardson AL; Delbridge L; Eng C; Robinson BG
Clin Endocrinol (Oxf); 1996 Mar; 44(3):249-57. PubMed ID: 8729519
[TBL] [Abstract][Full Text] [Related]
16. Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.
Grubbs EG; Williams MD; Scheet P; Vattathil S; Perrier ND; Lee JE; Gagel RF; Hai T; Feng L; Cabanillas ME; Cote GJ
Thyroid; 2016 Nov; 26(11):1553-1562. PubMed ID: 27610696
[TBL] [Abstract][Full Text] [Related]
17. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.
Ciampi R; Mian C; Fugazzola L; Cosci B; Romei C; Barollo S; Cirello V; Bottici V; Marconcini G; Rosa PM; Borrello MG; Basolo F; Ugolini C; Materazzi G; Pinchera A; Elisei R
Thyroid; 2013 Jan; 23(1):50-7. PubMed ID: 23240926
[TBL] [Abstract][Full Text] [Related]
18. High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas.
Simbolo M; Mian C; Barollo S; Fassan M; Mafficini A; Neves D; Scardoni M; Pennelli G; Rugge M; Pelizzo MR; Cavedon E; Fugazzola L; Scarpa A
Virchows Arch; 2014 Jul; 465(1):73-8. PubMed ID: 24828033
[TBL] [Abstract][Full Text] [Related]
19. mTOR activation in medullary thyroid carcinoma with RAS mutation.
Lyra J; Vinagre J; Batista R; Pinto V; Prazeres H; Rodrigues F; Eloy C; Sobrinho-Simões M; Soares P
Eur J Endocrinol; 2014 Nov; 171(5):633-40. PubMed ID: 25163725
[TBL] [Abstract][Full Text] [Related]
20. Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma.
Bim LV; Navarro FCP; Valente FOF; Lima-Junior JV; Delcelo R; Dias-da-Silva MR; Maciel RMB; Galante PAF; Cerutti JM
BMC Med Genomics; 2019 Jul; 12(1):104. PubMed ID: 31288802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
